Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO3300074 in moderate-to-severe COPD with emphysema
2006-002525-23Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palovarotene in chronic obstructive pulmonary disease (COPD) and emphysema (2 arms), sponsored by Roche. Primary endpoint: Post-bronchodilator clinic FEV1. Started Oct 2006; status: completed.
02
Drugs
palovarotene
03
Conditions
chronic obstructive pulmonary disease (COPD)emphysema
Beyond the preview
Go deeper on 2006-002525-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002525-23.